The oncology nutrition market in the United States is expected to be worth US$ 412.6 million. The U.S. presently holds 35.62% of the global oncology nutrition market share. Demand for oncology nutrition is predicted to increase in the United States, fueled by rising spending on various cancer medicines. NEWARK, DE / ACCESSWIRE / September 26, 2022 / The adoption of oncology nutrition is likely to grow at an average CAGR of 8.9% during the forecast period. The oncology nutrition market size is estimated to be valued at US$ 2.04 Bn in 2022 and is projected to be valued at US$ 4.79 Bn by 2032. The significant increase in nutritional waste and risk among cancer patients is expected to boost the demand for oncology nutrition. Participants in the market environment are currently examining the potential benefits of a multidisciplinary strategy, where concentrated nutrition is believed to be critical to enhancing cancer treatment standards. Over the estimated period, the oncology nutrition market is expected to benefit from increasing research and development efforts as well as the launch of cutting-edge products for cancer patients.
Baxter International Inc. with ticker code (BAX) have now 12 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 93 and 60 and has a mean target at 70.58. Now with the previous closing price of 58.97 this would indicate that there is a potential upside of 19.7%. There is a 50 day moving average of 60.69 and the 200 day MA is 74.02. The company has a market cap of $29,300m. Find out more information at: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $35,069m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
The agency issued its most serious type of recall for one of Baxter’s IV sets.
Baxter International Inc. (BAX)’s stock has witnessed a price hike of 1.27% from the previous close with its current price standing at $59.86. Its current price is -33.27% under its 52-week high of $89.70 and 9.93% more than its 52-week low of $54.45. Based on the past 30-day period, the stock price is -3.27% below […]
The U.S. Food and Drug Administration ((FDA)) on Thursday classified the recall of more than half a million drug delivery sets by Baxter (BAX) as the most serious type
Baxter stock has seen a 32% fall this year, underperforming the broader S&P500 index, down 17%.
Baxter International Inc. (BAX) earned favorable reviews from Bank of America and Well Fargo after Bloomberg reported Tuesday that the healthcare equipment maker was considering the sale…
Baxter International Inc. (BAX) is said to be considering the sale of two its kidney businesses.Baxter (BAX) is evaluating potential sales of its renal-care services and…
The share price of Baxter International Inc. (NYSE:BAX) fell to $58.70 per share on Thursday from $58.73. While Baxter International Inc. has underperformed by -0.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BAX fell by -29.07%, with highs and lows ranging from $89.70 to $54.45, […]
The global "Kidney Dialysis Equipment Market" report aims to provide a detailed analysis of the factors that influence the global business adoption and segmentation outlook. The detailed information and overview of the global Kidney Dialysis Equipment market report highlight the
The Unfractionated Heparin Market Industry research forecast to 2022-2028 offers in-depth market information to help companies develop growth strategies and make better business decisions based on forecasts and market trends. The study''s marketing variables include the dynamic market structure, key
Baxter International Inc. (NYSE:BAX)’s traded shares stood at 6.33 million during the last session, with the company’s beta value hitting 0.60. At the close of trading, the stock’s price was $58.73, to imply an increase of 7.45% or $4.07 in intraday trading. The BAX share’s 52-week high remains $89.70, putting it -52.73% down since that … Baxter International Inc. (NYSE: BAX) Has Fallen -52.73% From Its Highs, What Comes Next? Read More »
Baxter International Inc. (NYSE:BAX) price is hovering higher on Wednesday, September 07, jumping 4.79% above its previous close. A look at today’s price movement shows that the recent level at last check reads $54.66, with intraday deals fluctuating between $54.4521 and $56.53. The company’s 5Y monthly beta was ticking 0.68 while its P/E ratio in … Are Investors Eager To Sell Holdings In Baxter International Inc. (NYSE: BAX)? Read More »
In Thursday’s session, Baxter International Inc. (NYSE:BAX) marked $56.76 per share, down from $57.46 in the previous session. While Baxter International Inc. has underperformed by -1.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BAX fell by -26.86%, with highs and lows ranging from $89.70 to […]
Express (NYSE: EXPR ) stock is down by about 20% after the company reported its second-quarter earnings . Net income tallied in at $7.04 million, down about 33% compared to $10.6 million a year ago. On top of that, Express reported earnings per share (or EPS) of 10 cents, down from 15 cents year-over-year (YOY), but beating the consensus analyst estimate of nine cents. Total sales were up 1.6% YOY to $464.9 million, falling short of the analyst estimate of $479.6 million. Meanwhile, rising inflation has dampened consumer demand for clothing and accessories. Inventories were up 30% to $346.2 million. The rise was driven by the “pull-forward of purchases” to stay ahead of supply chain shortages and “pack-and-hold for late-arriving 2021 holiday inventory.” CEO Tim Baxter added: While we have lowered our outlook for the back half of this year to reflect the uncertainty of macroeconomic conditions, we remain committed to our long-term objective of a mid-single digit operating margin. We have demonstrated our ability to stay focused on the fundamentals, control the controllables, and operate with both discipline and agility.
The U.S. FDA has granted 510(k) clearance for Baxter International (BAX) Novum IQ syringe infusion pump with Dose IQ Safety Software.The pump is designed to deliver small amounts…
Baxter (NYSE:BAX) announced today that the FDA issued 510(k) clearance to its Novum IQ infusion pump with Dose IQ safety software. Deerfield, Illinois-based Baxter designed its new Novum IQ syringe infusion pump (SYR) to deliver small amounts of fluid at low rates. It includes a technologically integrated user experience with enhanced safety features. The system […] The post FDA clears syringe infusion pump with Dose IQ software from Baxter appeared first on Drug Delivery Business .
Baxter International (BAX) hit a 52-week low on Monday of $56.40.Year to date, shares are down 34%
Baxter International Inc. found using ticker (BAX) now have 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 100 and 60 calculating the mean target price we have 72.85. Given that the stocks previous close was at 57.17 this indicates there is a potential upside of 27.4%. The day 50 moving average is 62.75 and the 200 day moving average is 75.45. The market cap for the company is $28,585m. Find out more information at: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,425m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
Investors looking for a bargain might want to consider these 10 dividend stocks. Every stock on this list is near its 52-week lows, so this could present investors with a chance to buy the dip. What''s more, all of these stocks'' ex-dividend dates are coming up soon, so you still have a chance to grab some shares and benefit from their dividend distribution in the near future. Here is the full list: JWN, SPB, SLG, SSNC, UHS, BRKR, BAX, OTEX, SLM, SWK.
The share price of Baxter International Inc. (NYSE:BAX) rose to $59.92 per share on Thursday from $58.71. While Baxter International Inc. has overperformed by 2.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BAX fell by -18.81%, with highs and lows ranging from $89.70 to $57.49, […]
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, announces the national expansion of its partnership with international not-for-profit organization The Links, Incorporated (The Links) to continue bringing awareness and resources for the disproportionate challenges affecting Black Americans related to kidney health. Baxter is committing an incremental $800,000 in funding to The Links, specifically targeted toward expanding the program’s footprint t
Becton, Dickinson & Co convinced a Chicago federal judge on Monday that its system for moving hazardous drugs between syringes and drug vials does not infringe two patents owned by medical-device industry competitor Baxter International Inc.
Baxter International Inc. found using ticker (BAX) now have 13 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 100 and 60 calculating the average target price we see 72.85. With the stocks previous close at 61.05 this would imply there is a potential upside of 19.3%. The 50 day moving average now sits at 63.91 and the 200 moving average now moves to 75.94. The company has a market cap of $30,846m. Company Website: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,808m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
The Latest intelligence research report released by Stratagem Market Insights with the title "Peritoneal Dialysis Market Outlook, Development and Opportunities 2022-2030" is designed to cover a micro level of analysis with 120+ pages of analysis on business Strategies taken up
Coherent Market Insights has blazoned new analysis on Medical Nutrition Market Status 2022- 2028 which has been prepared grounded on an in- depth request analysis with inputs from assiduity experts and top merchandisers within the business. The report covers the
Baxter International Inc. found using ticker (BAX) have now 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 100 and 60 with a mean TP of 72.85. With the stocks previous close at 59.97 this is indicating there is a potential upside of 21.5%. The 50 day moving average now sits at 65.06 while the 200 day moving average is 76.4. The company has a market cap of $30,448m. Visit the company website at: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,988m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
Warner L Baxter , Executive Chairman at Ameren (NYSE: AEE ), reported a large insider sell on August 11, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Baxter sold 54,000 shares of Ameren . The total transaction amounted to $5,032,469. Ameren shares are trading up 0.72% at $94.71 at the time of this writing on Friday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insider transactions shouldn''t be used primarily to make … Full story available on Benzinga.com
Baxter boasts a broad portfolio of medically necessary products and therapies, and its brand strength is a key advantage. Click to read more.
Related Stocks: BAX , CVS , ZBH , MSFT , GOOGL ,
This has not been a kind year for investors. In fact, the S&P 500 fell 21% in the first half of the year. Further, on June 13 the index officially fell into bear-market territory as it closed 20% below the highs it reached in January. That means investors should logically seek to buy stocks that are in the best sectors for a bear market. The current bear market has caused investors to rethink their strategies. Moreover, successive bouts of quantitative tightening have raised interest rates, changing the entire market landscape. Companies that were able to survive and in some cases even thrive despite their suspect fundamentals have seen the rug pulled out from underneath them. Meanwhile, previously high-flying growth stocks have suddenly had to deal with a sea change in which they have abruptly begun to be considered overvalued and their prices have plummeted. That’s what bear markets do. They also cause investors to seek out new stock sectors that looked relatively unappealing during bull markets.
Baxter International Inc. found using ticker (BAX) now have 13 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 100 and 60 calculating the mean target price we have 72.85. Given that the stocks previous close was at 57.91 this would indicate that there is a potential upside of 25.8%. There is a 50 day moving average of 66.63 and the 200 day MA is 76.95. The market capitalisation for the company is $29,507m. You can visit the company''s website by visiting: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $37,119m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
Related Stocks: RBLX , SWN , NKE , WDAY , BAX ,
day’s top analyst upgrades and downgrades included Advanced Micro Devices, Baxter International, Caesars Entertainment, Electronic Arts, Exact Sciences, Gilead Sciences, Intel, JetBlue Airways, Marriott International, Match Group, Microchip Technology, Starbucks and Uber Technologies.
According to Benzinga Pro, during Q2, Baxter International (NYSE: BAX ) earned $255.00 million, a 249.32% increase from the preceding quarter. Baxter International also posted a total of $3.75 billion in sales, a 1.05% increase since Q1. In Q1, Baxter International earned $73.00 million, and total sales reached $3.71 billion. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of … Full story available on Benzinga.com
Investors weren''t happy with the company''s Q2 update.
Baxter International Inc (NYSE: BAX ) posted Q2 revenue of $3.75 billion , missing the consensus of $3.88 billion, up 21% on a reported basis, 26% on a constant currency basis, and 3% on an operational basis. Adjusted EPS of $0.87 increased 9%, in line with the consensus and the management guidance. Baxter''s newly acquired Hillrom businesses – Patient Support Systems, Front Line Care, and Surgical Solutions – contributed … Full story available on Benzinga.com
Baxter International Inc. (NYSE:NYSE:BAX) Q2 2022 Results Earnings Conference Call July 28, 2022, 08:30 AM ET Company Participants Clare Trachtman - Vice President, Investor Relations José…
Baxter (BAX) is scheduled to announce Q2 earnings results on Thursday, July 28th, before market open.The consensus EPS Estimate is $0.87 (+8.7% Y/Y) and the consensus Revenue Estimate…
Baxter International Inc. found using ticker (BAX) have now 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 100 and 70 calculating the average target price we see 84.85. Given that the stocks previous close was at 66.03 this would indicate that there is a potential upside of 28.5%. The 50 day moving average now sits at 69.04 and the 200 moving average now moves to 77.88. The company has a market cap of $33,313m. Company Website: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $42,809m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
Early Detection Can Prevent 95% of Vision Loss Cases SEOUL, South Korea , July 25, 2022 /PRNewswire/ -- Diabetic retinopathy is the leading cause of blindness among working-age adults globally. 1 With early detection and treatment, as much as 95 percent of vision loss cases can be prevented. 2 Compliance with annual diabetic retinal exams in South Korea was found to be approximately 53%, with only 73% of those taking place in the last 12 months. 3 Up to 80% of individuals with type two diabetes may eventually develop some stage of diabetic retinopathy. 4 The Welch Allyn® RetinaVue™ 100 Imager PRO enables diabetic retinopathy screening in primary care settings. By quickly and comfortably screening patients as part of their routine primary care visit, it has been shown that RetinaVue can double patient compliance for potentially vision-saving annual diabetic retinal exams (DREs) in 12 months. 5 "Diabetes is an epidemic. Diabetic retinopathy is the leading cause of vision loss among adults 20-to-74 years of age, 6 affecting 7.7 million people worldwide. 7 It is simply tragic that a large percentage of patients with diabetes aren''t being screened for diabetic retinopathy, when it''s one of the most preventable causes of blindness among adults," said Bruce Peatey, Vice President of Baxter, Asia Pacific . "RetinaVue has the potential to change lives by helping to identify diabetic retinopathy in those individuals who had not previously been screened for the disease, enhancing the potential to save the sight of thousands, if not millions, of people with diabetes." Baxter makes this possible by reducing the cost barrier for high-quality fundus imaging.
Fertility Drug Market 2022-2028 New Jersey, NJ -- ( SBWIRE ) -- 07/19/2022 -- 2022-2030 Report on Global Fertility Drug Market by Player, Region, Type, Application and Sales Channel is latest research study released by HTF MI evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Global Fertility Drug Market. Some of the key players profiled in the study are Merck, Ferring, MSD, LIVZON, Abbott, Bayer, Zydus Pharma, Berlex Laboratories, Baxter, Janssen, Pfizer, Takeda, P&G, Roche & Eli Lilly. Get free access to sample report @ https://www.htfmarketreport.com/sample-report/4097176-2022-2030-report-on-global-fertility-drug-market Fertility Drug Market Overview: The study provides comprehensive outlook vital to keep market knowledge up to date segmented by Female & Male, , Gonadotropins, Anti-Estrogens & Other and 18+ countries across the globe along with insights on emerging & major players.
Baxter International Inc. found using ticker (BAX) have now 13 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 100 and 70 and has a mean target at 85.62. Now with the previous closing price of 63.42 this would indicate that there is a potential upside of 35.0%. The 50 day MA is 69.8 and the 200 day MA is 78.26. The market cap for the company is $32,684m. You can visit the company''s website by visiting: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $44,125m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
Baxter International (BAX) underperformed its peers the past two years. Read more to see the Baxter''s potential headwinds and why I''m moving on from BAX stock.
The BAXTER FOR CONGRESS successfully filed their F3N JULY QUARTERLY with the coverage period of 04/01/2022 to 06/30/2022 and a confirmation ID of FEC-1613172 *********CommitteeId: C00783720 | FilingId: 1613172 | FormType: F3N | CoverageFrom: 04/01/2022 | CoverageThrough: 06/30/2022 | ReportType: JULY QUARTERLY*********
Baxter (NYSE:BAX) declares $0.29/share quarterly dividend, in line with previous.Forward yield 1.79%Payable Oct. 3; for shareholders of record Sept. 2; ex-div Sept.
Baxter International Inc. found using ticker (BAX) now have 13 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 100 and 70 with the average target price sitting at 86.54. Given that the stocks previous close was at 65.21 this now indicates there is a potential upside of 32.7%. The 50 day moving average now sits at 70.48 while the 200 day moving average is 78.68. The market cap for the company is $32,820m. You can visit the company''s website by visiting: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $43,555m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
At the age of 71, singer-songwriter Hoover is finally releasing her debut album – 50 years after she made it. She explains how Becker and Fagen lent a hand to a must-have record for Dan fans Few wannabe pop stars release their debut album at the age of 71, especially one that was recorded more than half a century earlier. But Linda Hoover’s I Mean to Shine is no ordinary album. Not only does the backing group feature three future members of Steely Dan – Donald Fagen, Walter Becker and Jeff “Skunk” Baxter – it also includes five Becker-Fagen songs, all of them little-known and one of them never previously heard. This historic pop artefact has gathered dust for 52 years after her label boss withheld the release. “I was not emotionally prepared when I was told the album was being shelved, and I felt like it was my fault,” says Hoover today. “I knew nothing about the music business, or any business for that matter. I was rolling along on the high of highs and suddenly it was over.” Back in the 1960s, Hoover was just a New Jersey kid with big dreams.
Digital agency Huge is laying off about 3% of the agency, CEO Mat Baxter confirmed to Adweek today. Baxter told Adweek that the agency, which has about 1,200 employees across 12 global markets, made the cuts in response to the changing market and clients cutting spend. "We''re seeing clients either cancel, move or pause activities,"…
Bolts fall to Colo-NESCO, state-ranked Ankeny Christian Academy in postseason play
- ← Previous
- 1
- 2
- 3
- …
- 8
- 9
- Next →